GURU.Markets stock price, segment price, and overall market index valuation
The company's share price TransCode Therapeutics
Shares of TransCode, a biotech company developing RNA therapies for cancer treatment, reflect the sector's binary risks. The price trajectory depends entirely on the results of preclinical and clinical trials.
Share prices of companies in the market segment - Dna
TransCode Therapeutics is an oncology company developing RNA-based drugs for the treatment of metastatic cancer. We've categorized it as "DNA," and the chart below shows how investors are evaluating innovative approaches to delivering therapeutic RNA directly to tumors.
Broad Market Index - GURU.Markets
TransCode Therapeutics is a biotech company developing RNA-based drugs for targeted cancer therapy. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how TransCode compares to it.
Change in the price of a company, segment, and market as a whole per day
RNAZ - Daily change in the company's share price TransCode Therapeutics
For TransCode Therapeutics, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reactions to news about the preclinical and clinical trials of its RNA therapy.
Daily change in the price of a set of shares in a market segment - Dna
TransCode Therapeutics is working on cutting-edge RNA therapeutics, making its shares extremely volatile. The chart below shows the average daily risk "pulse" in the gene therapy sector. It serves as a benchmark to understand that sharp fluctuations are normal for RNAZ shares.
Daily change in the price of a broad market stock, index - GURU.Markets
TransCode Therapeutics is a biotech company developing RNA interference-based drugs. The company's shares are a bet on a breakthrough in gene therapy. Their high, speculative volatility is part of the dynamic of the innovation sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization TransCode Therapeutics
For TransCode Therapeutics, the year-over-year trend is a story about the development of its platform for delivering RNA therapy to metastases. Its 12-month market cap is entirely dependent on preclinical and early clinical trial data. The success of its approach could lead to a breakthrough in the treatment of metastatic cancer, which is its main scientific bet.
Annual dynamics of market capitalization of the market segment - Dna
As an early-stage biotech, TransCode is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about its RNA therapy delivery platform. Its stock price will reflect investors' speculative belief in its potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
TransCode Therapeutics, with its cutting-edge RNA technology for cancer treatment, is one of the earliest and riskiest bets in biotech. Its performance relative to the market is pure speculation on the success of its scientific platform. Any promising result could trigger explosive growth.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization TransCode Therapeutics
TransCode is an early-stage biotech company developing a platform for delivering RNA therapeutics. Its monthly valuation is based solely on expectations. News about preclinical studies and the progress of its technology are the main drivers.
Monthly dynamics of market capitalization of the market segment - Dna
TransCode Therapeutics, Inc. is a biopharmaceutical company developing a new class of RNA-based therapies for the treatment of metastatic cancer. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how its unique platform for delivering therapeutic agents directly to cancer cells is progressing in preclinical and clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
TransCode Therapeutics develops RNA-based drugs for cancer treatment. It's a biotech company whose value depends on the success of its platform. The chart shows monthly fluctuations that reflect not overall market sentiment, but investor faith in this breakthrough technology.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization TransCode Therapeutics
TransCode Therapeutics is developing an RNA-based therapy for cancer. Its weekly stock price represents a highly volatile bet on the success of this cutting-edge, yet risky, technology. Clinical data is the main driver.
Weekly dynamics of market capitalization of the market segment - Dna
TransCode Therapeutics develops RNA-based drugs for cancer treatment. The chart shows how this innovative company's stock performs compared to the DNA and RNA therapeutics sector. Is its volatility a price to pay for breakthrough technologies or a common feature of the entire niche?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
TransCode Therapeutics is another biotech company whose stock exists in its own universe, reacting to clinical trial data. The chart clearly demonstrates how its weekly performance is isolated from general market fluctuations, following its own unique scientific trajectory.
Market capitalization of the company, segment and market as a whole
RNAZ - Market capitalization of the company TransCode Therapeutics
The TransCode Therapeutics chart shows a bet on revolutionary RNA therapy delivery. The company's market cap reflects investors' faith in its platform for targeted drug delivery to metastatic tumors. This highly volatile curve is driven by news about preclinical studies.
RNAZ - Share of the company's market capitalization TransCode Therapeutics within the market segment - Dna
TransCode Therapeutics is a biopharmaceutical company developing RNA-based drugs for the treatment of metastatic cancer. In the cutting-edge DNA/RNA medicine segment, its market capitalization reflects the potential of its unique delivery platform. The company's size reflects its bet on precisely delivering therapeutic RNA to cancer cells, a key challenge in this field.
Market capitalization of the market segment - Dna
TransCode Therapeutics is developing RNA therapy for the treatment of metastases. How big is this revolutionary arena? The chart below shows the pulse of the DNA technology sector. Its extreme volatility reflects both the enormous potential to combat the most deadly forms of cancer and the high risks of this cutting-edge science.
Market capitalization of all companies included in a broad market index - GURU.Markets
The TransCode Therapeutics chart shows how the market values its cutting-edge technology for delivering RNA therapy to metastatic tumors. The company's market cap represents a venture bet on its unique platform. This chart is fraught with scientific risk, but it holds the potential to solve one of the most complex challenges in oncology.
Book value capitalization of the company, segment and market as a whole
RNAZ - Book value capitalization of the company TransCode Therapeutics
The book value of TransCode Therapeutics, which is developing RNA therapy for metastatic cancer, is its tangible capital, consisting of the rights to the TTX delivery platform and financial reserves for R&D. The chart below shows how this scientific and financial capital has changed.
RNAZ - Share of the company's book capitalization TransCode Therapeutics within the market segment - Dna
TransCode Therapeutics is an RNA therapeutics company. Its tangible assets are the laboratories where its unique platform for delivering drugs directly to cancer cells is being developed. These R&D centers are its physical base for innovation. The chart shows the share of this specialized scientific infrastructure the company controls.
Market segment balance sheet capitalization - Dna
TransCode Therapeutics is a biotechnology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. TransCode focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
TransCode's assets are not drugs, but a scientific platform for the targeted delivery of therapeutic RNA to metastatic tumors. Its book value reflects its laboratory facilities and the capital invested in clinical trials of this "smart" approach to cancer treatment.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - TransCode Therapeutics
TransCode Therapeutics is developing RNA therapy for cancer treatment. Its value lies in its delivery platform. The chart shows how the market is pricing this cutting-edge, yet highly risky, scientific approach.
Market to book capitalization ratio in a market segment - Dna
TransCode Therapeutics develops RNA-based therapeutics for the treatment of metastatic cancer. This is cutting-edge science. The chart shows that the company's market value is based on expectations for its unique tumor drug delivery platform.
Market to book capitalization ratio for the market as a whole
TransCode Therapeutics is developing an RNA-based therapy. Its entire value lies in its intellectual property and the promise of a future breakthrough in metastatic cancer treatment. This chart illustrates the enormous premium to book value that investors are willing to pay for cutting-edge science.
Debts of the company, segment and market as a whole
RNAZ - Company debts TransCode Therapeutics
TransCode Therapeutics is developing RNA therapy for the treatment of metastatic cancer. This is a cutting-edge, yet early-stage technology that requires significant investment in research. This chart shows how the company is raising capital to fund its preclinical and early clinical trials, which are its primary and most valuable asset.
Market segment debts - Dna
TransCode Therapeutics is a preclinical biotech company developing a platform for delivering RNA therapeutics to tumors. Its technology is in the very early stages. This graph reflects its complete reliance on equity capital to fund its fundamental research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio TransCode Therapeutics
TransCode Therapeutics is an early-stage biotech company working in RNA therapeutics. This chart shows its financial structure. For a company focused on basic science, debt is an extreme risk. All funding must be equity-based.
Market segment debt to market segment book capitalization - Dna
TransCode Therapeutics is developing RNA-based therapeutics for the treatment of metastatic cancer. This is a cutting-edge, but highly risky, field. The chart shows the overall debt burden in the biotech sector, highlighting the enormous financial resources the company requires to advance its innovative technology through clinical trials.
Debt to book value of all companies in the market
TransCode Therapeutics, Inc. is developing RNA therapy for the treatment of metastatic cancer. This is cutting-edge research. This chart, reflecting the debt of an established economy, highlights that TransCode's funding is entirely dependent on investors' faith in the potential of its platform, rather than traditional loans that require stable revenue.
P/E of the company, segment and market as a whole
P/E - TransCode Therapeutics
For TransCode Therapeutics, a company developing RNA-based therapies for cancer, the P/E ratio is not applicable. The company is not profitable, and its valuation on this chart is arbitrary. It is a speculative bet that its innovative approach to delivering therapeutic molecules to tumors will be successful.
P/E of the market segment - Dna
TransCode Therapeutics is an early-stage biopharmaceutical company developing RNA-based therapeutics for the treatment of metastatic cancer. This chart shows the average valuation for the sector, providing investors with context for evaluating this cutting-edge, yet high-risk, scientific platform.
P/E of the market as a whole
TransCode Therapeutics is a biotech company developing RNA-based therapies for the treatment of metastatic cancer. Its valuation is a pure bet on its scientific platform and is not tied to the general economic cycles depicted by this chart. TransCode's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company TransCode Therapeutics
TransCode Therapeutics is a biotech company developing RNA-based drugs for the treatment of metastatic cancer. This chart reflects investor expectations for its unique platform for delivering therapeutic RNA to tumors. The valuation is based on the long-term potential of this breakthrough technology.
%20P%2FE%20TransCode%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-TransCode-Therapeutics&v=1772513459513 "Chart of the company's future (projected) P/E TransCode Therapeutics")
Future (projected) P/E of the market segment - Dna
TransCode Therapeutics is developing RNA-based therapies for the treatment of metastatic cancer. Its valuation relative to other oncology biotechs reflects investor sentiment about its innovative delivery platform. This is a bet that its technology can effectively deliver therapeutic molecules directly to tumor cells.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772513459516 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
TransCode Therapeutics develops RNA-based drugs for targeted cancer therapy. Its technology aims to deliver drugs directly to metastatic cells. This is cutting-edge science. This chart shows the overall risk appetite of investors. For biotech companies with breakthrough, but very early, technologies, a positive environment is important for funding long-term research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513459520 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit TransCode Therapeutics
TransCode Therapeutics is an early-stage oncology company developing a platform for delivering therapeutic RNA directly to metastatic tumors. The financial performance shown here reflects the preclinical development costs of this cutting-edge and risky technology.
Profit of companies in the market segment - Dna
TransCode Therapeutics develops RNA-based drugs for targeted cancer therapy. This chart reflects the financial status of the DNA/RNA therapeutics sector. It demonstrates how close this cutting-edge scientific field is to creating commercially viable products capable of competing with traditional treatments.
Overall market profit
TransCode Therapeutics develops RNA-based therapeutics for the treatment of metastatic cancer. This is a cutting-edge scientific field. The company's value depends on the potential of its platform and research results. Macroeconomic cycles, as seen in this chart, are not of great importance for RNAZ.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company TransCode Therapeutics
TransCode Therapeutics develops RNA-based therapeutics for cancer treatment. Its future revenue forecast is a long-term bet on the success of its innovative platform. This chart reflects analysts' confidence in the potential of its technology to create a new class of drugs against metastatic cancer.
%20profit%20of%20the%20company%20TransCode%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-TransCode-Therapeutics&v=1772513459525 "Graph of future (projected) profit of the company TransCode Therapeutics")
Future (predicted) profit of companies in the market segment - Dna
TransCode Therapeutics is developing RNA-based therapeutics for the treatment of metastatic cancer. Their technology aims to deliver drugs directly to metastases. This chart shows forecasts for the DNA therapy segment. It illustrates the importance of scientific breakthroughs in drug delivery for the success of gene therapy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772513459526 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
For TransCode Therapeutics, which operates in the cutting-edge field of RNA therapeutics, this chart is important for capital availability. A positive economic outlook increases investor willingness to finance breakthrough but risky technologies. A negative trend could complicate raising funds for research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513459527 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - TransCode Therapeutics
TransCode Therapeutics is developing an RNA-based therapy for the treatment of metastatic cancer. This figure, without revenue, is a pure measure of expectations. Investors evaluate scientific potential, not current cash flows.
P/S market segment - Dna
TransCode Therapeutics is a biopharmaceutical company developing RNA-based therapeutics for the treatment of metastatic cancer. This chart shows the average valuation in the DNA technology sector. It reflects investor expectations for TransCode's innovative platform, which targets previously considered inaccessible genetic targets.
P/S of the market as a whole
TransCode Therapeutics, Inc. is an early-stage RNA-based oncology company developing a therapeutic platform for the treatment of metastatic cancer. The company's valuation is based on the potential of its drug delivery technology for metastases. This chart shows the market premium for technologies aimed at solving the most complex problems in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company TransCode Therapeutics
TransCode Therapeutics is developing RNA-based therapies for the treatment of metastatic cancer. The company's valuation is based on the future potential of its drug delivery platform. The chart reflects investors' belief that its technology can effectively deliver therapeutic molecules to tumors.
%20P%2FS%20TransCode%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-TransCode-Therapeutics&v=1772513459531 "The graph of the company's future (projected) P/S TransCode Therapeutics")
Future (projected) P/S of the market segment - Dna
TransCode Therapeutics is an oncology company developing RNA-based drugs for the treatment of metastatic cancer. Its technology aims to deliver therapeutic RNA directly to metastases. This chart shows how investors view the potential of this cutting-edge and risky technology.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772513459532 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
This chart illustrates investor sentiment in the gene therapy field. For TransCode Therapeutics, a company developing a system for delivering RNA therapy to metastatic tumors, this is a sign of faith in the future. Market optimism is essential for funding breakthrough platforms that can solve the main problem in oncology: metastasis.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513459532 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales TransCode Therapeutics
TransCode Therapeutics is an oncology company developing RNA-based drugs for the treatment of metastatic cancer. Its technology aims to deliver therapeutic molecules directly to metastases. This graph reflects grant revenue. Future revenue is dependent on the success of clinical trials of this new approach.
Sales of companies in the market segment - Dna
TransCode Therapeutics is an oncology company developing RNA-based drugs for the treatment of metastatic cancer. This chart illustrates the growth of the gene therapy sector. TransCode's unique delivery platform targets metastases, the leading cause of cancer death and one of the most challenging areas in oncology.
Overall market sales
TransCode Therapeutics develops RNA-based therapeutics for the treatment of metastatic cancer. The company's growth depends on investment in its scientific platform. The overall economic environment, shown in this chart, influences investors' risk appetite and their willingness to invest in cutting-edge scientific research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company TransCode Therapeutics
TransCode Therapeutics is developing RNA-based therapeutics for the treatment of metastatic cancer. Its technology aims to deliver RNA drugs directly to cancer cells. This schedule reflects analysts' expectations for the success of preclinical and early clinical trials of this innovative platform.
%20sales%20of%20the%20company%20TransCode%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-TransCode-Therapeutics&v=1772513459543 "Schedule of future (projected) sales of the company TransCode Therapeutics")
Future (projected) sales of companies in the market segment - Dna
TransCode Therapeutics is developing RNA-based therapeutics for the treatment of metastatic cancer. This chart shows the expectations for the DNA technology sector. It illustrates the potential of using RNA to deliver drugs directly to cancer cells, a cutting-edge approach in oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772513459548 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
TransCode Therapeutics, Inc. is an RNA-based oncology company developing a new class of therapeutics for the treatment of metastatic cancer. Its future depends on the success of its delivery platform. This schedule, reflecting the state of the economy, affects the availability of capital to finance the breakthrough, but high-risk, oncology technologies TransCode is developing.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513459550 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality TransCode Therapeutics
TransCode Therapeutics is developing an RNA-based therapy for the treatment of metastatic cancer. This chart shows the financial status of the early-stage research. Negative values represent investments in a unique delivery technology designed to precisely target cancer cells and "turn off" their growth.
Market segment marginality - Dna
TransCode Therapeutics is a biopharmaceutical company developing RNA-based drugs for the treatment of metastatic cancer. For a company in the research stage, this chart serves as a benchmark. It shows the average profitability in their sector, illustrating the financial potential that could be realized if their innovative approach is successful.
Market marginality as a whole
TransCode Therapeutics is an early-stage biopharmaceutical company developing RNA-based drugs for the treatment of metastatic cancer. This overall market profitability schedule is irrelevant to the company. Its potential lies in developing a breakthrough technology. Success will be determined by the results of preclinical and early clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company TransCode Therapeutics
TransCode Therapeutics is an early-stage oncology company developing a platform for delivering RNA therapeutics directly to cancer cells. This graphic shows the small team of scientists working on this cutting-edge technology.
Share of the company's employees TransCode Therapeutics within the market segment - Dna
TransCode Therapeutics is developing RNA-based therapies for the treatment of metastatic cancer. This chart shows the percentage of leading biologists, nanotechnologists, and oncologists working in this cutting-edge field that the company attracts. It reflects its concentration of unique scientific talent for delivering drugs directly to cancer cells.
Number of employees in the market segment - Dna
TransCode Therapeutics is developing RNA-based therapies for the treatment of metastatic cancer. Precise drug delivery to metastases is one of the most challenging tasks in oncology. This graph shows how companies at the forefront of science are solving fundamental problems, requiring the involvement of top biologists and chemists to create breakthrough technologies.
Number of employees in the market as a whole
TransCode Therapeutics is developing a new class of RNA therapeutics. This is fundamental science, just steps away from the clinic. This graph shows the current economy, but it is in the labs of companies like RNAZ that technologies are being born that could lead to the creation of entirely new industries and jobs in the future.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company TransCode Therapeutics (RNAZ)
TransCode Therapeutics is a biotech company developing RNA therapeutics for cancer treatment. This chart represents the net intellectual capital valuation. The company's value is based on market expectations for its unique delivery platform (TTX). The chart shows how highly the market values this scientific potential per scientist working on it.
%20of%20the%20company%20TransCode%20Therapeutics%20(RNAZ)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-TransCode-Therapeutics-RNAZ&v=1772513459587 "Chart of market capitalization per employee (in thousands of dollars) of the company TransCode Therapeutics (RNAZ)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
TransCode Therapeutics is developing RNA-based drugs for the treatment of metastatic cancer. This is the cutting edge of oncology. The chart shows the enormous value the market places on each scientist working on this breakthrough technology. This reflects the high expectations for their therapeutic approach.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772513459587 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
TransCode Therapeutics is a biopharmaceutical company developing RNA-based therapies for the treatment of metastatic cancer. This chart shows the average market cap per employee, highlighting the enormous value the market places on breakthrough scientific platforms.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513459594 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company TransCode Therapeutics (RNAZ)
TransCode Therapeutics is a clinical-stage biotech company working with RNA. The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company invests in each scientist for R&D.
%20Chart%20TransCode%20Therapeutics%20(RNAZ)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-TransCode-Therapeutics-RNAZ&v=1772513459595 "Company Profit Per Employee (in thousands of dollars) Chart TransCode Therapeutics (RNAZ)")
Profit per employee (in thousands of dollars) in the market segment - Dna
TransCode Therapeutics is developing RNA-based therapeutics for the treatment of metastatic cancer. It is an early-stage biotech company. The negative earnings per employee (EPE), which this chart likely shows, is industry norm and reflects significant investment in its scientific team and cutting-edge technologies.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772513459598 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
TransCode Therapeutics (RNAZ) is an R&D-stage biotech company developing RNA therapeutics (RNAi) for the treatment of cancer (particularly metastases). Their focus is on delivery systems. This is an R&D business. This chart shows the market average dollar return per employee. For RNAZ (which is not yet profitable), this is a benchmark: in biotech, IP allows them to exceed this average many times over.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513459607 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee TransCode Therapeutics (RNAZ)
TransCode Therapeutics is an early-stage oncology company developing RNA-based therapeutics. This graph reflects the very beginning of its biotech journey, demonstrating potential that can only be realized after years of research, development, and clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-TransCode-Therapeutics-RNAZ&v=1772513459625 "Sales chart per company employee TransCode Therapeutics (RNAZ)")
Sales per employee in the market segment - Dna
TransCode Therapeutics is a biotech company developing an RNA therapeutic delivery platform for cancer treatment. The company is in the R&D stage. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial pharmaceutical companies and helps evaluate the effectiveness of TransCode's scientific team.
Sales per employee for the market as a whole
TransCode Therapeutics is an early-stage biotech company developing an RNA therapy delivery platform for cancer treatment. The company has no commercial revenue, which is irrelevant. Its value lies in the potential of its R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company TransCode Therapeutics (RNAZ)
TransCode Therapeutics is a very early, preclinical stage biotech company exploring the use of RNA therapy to treat cancer. This is a highly speculative venture bet. This chart shows the number of investors who believe the company's chances of bringing its product to market are close to zero and that it will run out of money.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-TransCode-Therapeutics-RNAZ&v=1772513459662 "Short Shares Chart for the Company TransCode Therapeutics (RNAZ)")
Shares shorted by market segment - Dna
TransCode Therapeutics (RNAZ) is an oncology company developing RNA-based drugs (RNA interference) for the treatment of metastatic cancer. This chart reflects the total short position in the biotech sector (DNA/RNA therapeutics). High values indicate general investor skepticism about the success of clinical trials of these cutting-edge technologies.
Shares shorted by the overall market
TransCode (RNAZ) is a clinical-stage biotech company working with RNA. Its value reflects its hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, requiring refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator TransCode Therapeutics (RNAZ)
TransCode Therapeutics (RNAZ) is a preclinical biotech developing an RNA-based platform for the treatment of metastatic cancer. This is a highly speculative area. This chart measures the strength of sharp price movements. It shows when bursts of enthusiasm (above 70) or periods of disappointment (below 30) peak, signaling a potential reversal.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-TransCode-Therapeutics-RNAZ&v=1772513459665 "RSI 14 indicator chart for the company's stock TransCode Therapeutics (RNAZ)")
RSI 14 Market Segment - Dna
TransCode Therapeutics is a biotech company developing RNA-based therapies for cancer. Their approach aims to "knock out" genes that cause metastasis. This graph measures the collective momentum in the gene and RNA therapy sector. It helps distinguish the reaction to RNAZ's clinical data from the general "emotional" wave sweeping the entire industry.
RSI 14 for the overall market
TransCode Therapeutics (RNAZ) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RNAZ (TransCode Therapeutics)
TransCode Therapeutics is a biotech company developing a platform (TTX) for delivering RNA therapeutics directly to tumors. This chart shows the average target price. Analysts' estimates are based on preclinical and early clinical data, as well as the potential of their delivery system.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RNAZ-TransCode-Therapeutics&v=1772513459677 "A chart showing analyst consensus forecasts for the expected stock price. RNAZ (TransCode Therapeutics)")
The difference between the consensus estimate and the actual stock price RNAZ (TransCode Therapeutics)
TransCode is a biotech company developing a platform for delivering RNA-based therapies (targeting microRNA) for cancer treatment. This chart shows the difference between the market valuation and the consensus forecast. It reflects the confidence of experts in their R&D platform and tumor drug delivery technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RNAZ-TransCode-Therapeutics&v=1772513459679 "A chart showing the difference between the consensus forecast and the actual stock price. RNAZ (TransCode Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Dna
TransCode Therapeutics is a biotech company developing a new platform (TTX) for delivering RNA therapeutics (to "silence" cancer genes) directly into tumors. This chart shows general expectations for the DNA technology sector. It reflects whether experts believe in a breakthrough in targeted RNA drug delivery.
Analysts' consensus forecast for the overall market share price
TransCode Therapeutics (RNAZ) is an early-stage biopharmaceutical company working on RNA-based therapies for delivering drugs directly to cancer cells. This is highly speculative science. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for biotechs that don't yet have revenue.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index TransCode Therapeutics
TransCode is a delivery system for RNA therapy. Their key feature isn't the drug (RNA) itself, but the delivery system (TTX), which (they claim) can safely deliver the gene-killer directly to tumors. This graph is a pure indicator of their R&D. It reflects their (very long) journey and the market's confidence that their delivery system actually works.
AKIMA Market Segment Index - Dna
TransCode Therapeutics (RNAZ) uses RNA interference (RNAi) to combat metastatic cancer. Their platform delivers gene switches (RNA) to cancer cells to stop their spread. This chart shows the segment average. It helps investors assess how this cutting-edge but risky technology compares to the average.
The AKIM Index for the overall market
TransCode Therapeutics is a biotech company developing RNA-based oncology therapies using nanoparticle delivery. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this early scientific story compares to overall economic trends.
